1. Academic Validation
  2. HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin

HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin

  • Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14.
Nancy Yu 1 Michael Kakunda 1 Victoria Pham 2 Jennie R Lill 2 Pan Du 3 Matthew Wongchenko 4 Yibing Yan 4 Ron Firestein 5 XiaoDong Huang 6
Affiliations

Affiliations

  • 1 Department of Discovery Oncology, Genentech, Inc., South San Francisco, California, USA.
  • 2 Department of Protein Chemistry, Genentech, Inc., South San Francisco, California, USA.
  • 3 Department of Bioinformatics, Genentech, Inc., South San Francisco, California, USA.
  • 4 Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, USA.
  • 5 Department of Pathology, Genentech, Inc., South San Francisco, California, USA.
  • 6 Department of Discovery Oncology, Genentech, Inc., South San Francisco, California, USA [email protected].
Abstract

The Wnt/β-catenin pathway causes accumulation of β-catenin in the cytoplasm and its subsequent translocation into the nucleus to initiate the transcription of the target genes. Without Wnt stimulation, β-catenin forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), Casein Kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β) and undergoes phosphorylation-dependent ubiquitination. Phosphatases, such as protein Phosphatase 2A (PP2A), interestingly, also are components of this degradation complex; therefore, a balance must be reached between phosphorylation and dephosphorylation. How this balance is regulated is largely unknown. Here we show that a heat shock protein, HSP105, is a previously unidentified component of the β-catenin degradation complex. HSP105 is required for Wnt signaling, since depletion of HSP105 compromises β-catenin accumulation and target gene transcription upon Wnt stimulation. Mechanistically, HSP105 depletion disrupts the integration of PP2A into the β-catenin degradation complex, favoring the hyperphosphorylation and degradation of β-catenin. HSP105 is overexpressed in many types of tumors, correlating with increased nuclear β-catenin protein levels and Wnt target gene upregulation. Furthermore, overexpression of HSP105 is a prognostic biomarker that correlates with poor overall survival in breast Cancer patients as well as melanoma patients participating in the BRIM2 clinical study.

Figures